The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares details of a consensus paper to guide physicians on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma. Dr Beksac highlights the importance of close collaboration with ophthalmologists and notes that strategies are being developed across the globe to manage these toxicities. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Belantamab is an antibody-drug conjugate, which is very effective and which has been shown in both the DREAMM-7 and DREAMM-8 studies. And what we did was recently to write a consensus paper on how to approach ocular toxicity, which is the leading toxicity of this specific drug. And based on our experience in the DREAMM-8 and also on now our ongoing early access program, we are more confident that we can manage this ocular toxicity...
Belantamab is an antibody-drug conjugate, which is very effective and which has been shown in both the DREAMM-7 and DREAMM-8 studies. And what we did was recently to write a consensus paper on how to approach ocular toxicity, which is the leading toxicity of this specific drug. And based on our experience in the DREAMM-8 and also on now our ongoing early access program, we are more confident that we can manage this ocular toxicity. And in a very close collaboration with our ophthalmologists in the region, similar to another effort from the LATAM and also from Asia, different countries. People are gathering together to develop their own strategies to manage ocular toxicity. And we developed an algorithm to guide the physicians how to approach patients on each cycle. Should they be referred to an ophthalmologist on every cycle or based on the symptoms and how to give these patients the prophylaxis, the cold pads, the eye drops that they should be using. So these were all described in detail to give us a reference for clinical use.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
